Developing drugs for use before, during and soon after percutaneous coronary intervention.

about

Current and novel approaches to treat patients presenting with ST elevation myocardial infarction.Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease.

P2860

Q38855389-C9598B91-8621-4004-A3A8-B23F285D2BD3 Q39093174-BCCA752C-C967-4DDC-8553-48011C62C914

P2860

Developing drugs for use before, during and soon after percutaneous coronary intervention.

Item

http://www.wikidata.org/entity/Q38708145

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Developing drugs for use befor ...... taneous coronary intervention.

@en

type

Item

label

Developing drugs for use befor ...... taneous coronary intervention.

@en

prefLabel

Developing drugs for use befor ...... taneous coronary intervention.

@en

P1476

Developing drugs for use before, during and soon after percutaneous coronary intervention

@en

P2093

Aris Moschovitis

http://www.w3.org/2001/XMLSchema#string

Stephan Windecker

http://www.w3.org/2001/XMLSchema#string

P2860

2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials

The "no reflow" phenomenon following acute myocardial infarction: mechanisms and treatment options

Short-term effect of verapamil on coronary no-reflow associated with percutaneous coronary intervention in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized controlled trials

Improvement in microvascular reflow and reduction of infarct size with adenosine in patients undergoing primary coronary stenting.

Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.

Intracoronary versus intravenous bolus abciximab administration in patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial infarction: a pooled analysis of individual patient data from five randomised contro

Argatroban for elective percutaneous coronary intervention: the ARG-E04 multi-center study.

Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial.

Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.

P304

803-818

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2016.1145666

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Marco Valgimigli

Giuseppe Gargiulo

P577

2016-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26800365

http://www.w3.org/2001/XMLSchema#string

Developing drugs for use before, during and soon after percutaneous coronary intervention.

about

P2860

P2860

Developing drugs for use before, during and soon after percutaneous coronary intervention.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698